Showing results (291-300 of 409) with videos related to
Sort By:
Pageof 41
Journal of Immunology (Baltimore, Md. : 1950)|January 1, 1975
The release of four mediators of immediate hypersensitivity from human leukemic basophilsR A Lewis, E J Goetzl, S I Wasserman, et al.The Journal of Clinical Investigation|December 1, 1979
Isolation and characterization of heparin from human lungD D Metcalfe, R A Lewis, J E Silbert, et al.Proceedings of the National Academy of Sciences of the United States of America|May 1, 1981
Contractile activities of structural analogs of leukotrienes C and D: necessity of a hydrophobic regionJ M Drazen, R A Lewis, K F Austen, et al.Physics in Medicine and Biology|August 1, 2007
Analyser-based phase contrast image reconstruction using geometrical opticsM J Kitchen, K M Pavlov, K K W Siu, et al.American Journal of Human Genetics|July 1, 1991
Three different frameshift mutations of the tyrosinase gene in type IA oculocutaneous albinismW S Oetting, M M Mentink, C G Summers, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 1, 1988
Leukotriene C4 produced by a human T-T hybridoma suppresses Ig production by human lymphocytesJ L Ambrus, C H Jurgensen, N L Witzel, et al.Proceedings of the National Academy of Sciences of the United States of America|December 1, 1983
Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4P F Weller, C W Lee, D W Foster, et al.The Journal of Allergy and Clinical Immunology|April 1, 1985
Exercise-induced anaphylaxis: a serious form of physical allergy associated with mast cell degranulationA L Sheffer, A K Tong, G F Murphy, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 15, 1987
The effects of N-3 polyunsaturated fatty acids on the generation of platelet-activating factor-acether by human monocytesR I Sperling, J L Robin, K A Kylander, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|January 25, 2002
A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapyO A Khan, A C Tselis, J A Kamholz, et al.Pageof 41